Goldman misses bond fees as Abbott wins Solvay race

LONDON (Reuters) – Solvay’s 4.5 billion euro ($6.6 billion) drug unit sale to Abbott Laboratories has wrongfooted Wall Street heavyweights such as Goldman Sachs, who had stood to earn tens of millions of dollars from rival bidder Nycomed.

Leave a Reply